The ubiquitin–proteasome system and assays to determine responses to inhibitors

Author： Tsvetkov Lyuben Nanjundan Meera Domino Maria Daniel Kenyon G

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.5, Iss.12, 2010-12, pp. : 1221-1236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 517-536

Bentham Science Publishers

Access to resources Recommend Favorite

Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway

Current Drug Targets, Vol. 12, Iss. 11, 2011-10 ,pp. : 1581-1594

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?

Current Molecular Pharmacology, Vol. 1, Iss. 1, 2008-01 ,pp. : 24-37

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the ubiquitin-proteasome system for cancer therapy

By Shen Min

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 9, 2013-09 ,pp. : 1091-1108

Informa Healthcare

Access to resources Recommend Favorite

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib

Current Pharmaceutical Design, Vol. 17, Iss. 15, 2011-05 ,pp. : 1483-1499

Bentham Science Publishers

Access to resources Recommend Favorite